Skip to main content
Darren Carpizo, MD, General Surgery, Rochester, NY, Strong Memorial Hospital of the University of Rochester

DarrenRCarpizoMD

General Surgery Rochester, NY

Surgical Oncology (Other than Breast)

Assistant Professor, Surgery, UMDNJ-Robert Wood Johnson Medical School

Dr. Carpizo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Carpizo's full profile

Already have an account?

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Surgery, 1997 - 2006
  • University of Illinois College of Medicine
    University of Illinois College of MedicineClass of 1997

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1999 - Present
  • NY State Medical License
    NY State Medical License 2006 - 2025
  • NJ State Medical License
    NJ State Medical License 2008 - 2021
  • American Board of Surgery Surgery

Awards, Honors, & Recognition

  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Neoadjuvant Chemoradiation Improves Margin Positivity Rates After Pancreaticoduodenectomy in T1 and T2 Resectable Pancreatic Cancer: An Analysis of the National Cancer...  
    Mihir M Shah, Darren R Carpizo, Miral S Grandhi, Russell C Langan, Journal of The American College of Surgeons

Authored Content

  • Neoadjuvant Chemoradiation Improves Margin Positivity Rates After Pancreaticoduodenectomy in T1 and T2 Resectable Pancreatic Cancer: An Analysis of the National Cancer DatabaseOctober 2018

Press Mentions

  • $500K Grant Aids Exploration of Genetic Changes in Pancreatic Cancer for New Treatment Targets
    $500K Grant Aids Exploration of Genetic Changes in Pancreatic Cancer for New Treatment TargetsAugust 23rd, 2018
  • Meet Our 2018 Research Grantees: Translational Awards
    Meet Our 2018 Research Grantees: Translational AwardsJuly 18th, 2018
  • Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer
    Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal CancerJuly 11th, 2018
  • Join now to see all

Professional Memberships

Hospital Affiliations